These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 30969080)
1. Prognostic Impact of WT-1 and Survivin Gene Expression in Acute Myeloid Leukemia Patients. Adnan-Awad S; Meligui YME; Salem SE; Salaheldin O; Ayoub MA; Kamel MM Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969080 [TBL] [Abstract][Full Text] [Related]
2. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. Damm F; Heuser M; Morgan M; Yun H; Grosshennig A; Göhring G; Schlegelberger B; Döhner K; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Döhner H; Heil G; Ganser A; Krauter J J Clin Oncol; 2010 Feb; 28(4):578-85. PubMed ID: 20038731 [TBL] [Abstract][Full Text] [Related]
3. Combinatorial molecular marker assays of WT1, survivin, and TERT at initial diagnosis of adult acute myeloid leukemia. Kim HJ; Choi EJ; Sohn HJ; Park SH; Min WS; Kim TG Eur J Haematol; 2013 Nov; 91(5):411-22. PubMed ID: 23826993 [TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Gaidzik VI; Schlenk RF; Moschny S; Becker A; Bullinger L; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Döhner H; Döhner K; Blood; 2009 May; 113(19):4505-11. PubMed ID: 19221039 [TBL] [Abstract][Full Text] [Related]
5. WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. Miglino M; Colombo N; Pica G; Grasso R; Clavio M; Bergamaschi M; Ballerini F; Ghiso A; Ghiggi C; Mitscheunig L; Beltrami G; Cagnetta A; Vignolo L; Lucchetti MV; Aquino S; Pierri I; Sessarego M; Carella AM; Gobbi M Leuk Lymphoma; 2011 Oct; 52(10):1961-9. PubMed ID: 21942328 [TBL] [Abstract][Full Text] [Related]
6. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia. Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598 [TBL] [Abstract][Full Text] [Related]
7. Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study. Hidaka D; Onozawa M; Hashiguchi J; Miyashita N; Kasahara K; Fujisawa S; Hayase E; Okada K; Shiratori S; Goto H; Sugita J; Nakagawa M; Hashimoto D; Kahata K; Endo T; Yamamoto S; Tsutsumi Y; Haseyama Y; Nagashima T; Mori A; Ota S; Sakai H; Ishihara T; Imai K; Miyagishima T; Kakinoki Y; Kurosawa M; Kobayashi H; Iwasaki H; Shimizu C; Kondo T; Teshima T Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e469-e479. PubMed ID: 30082223 [TBL] [Abstract][Full Text] [Related]
8. Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients. Marjanovic I; Karan-Djurasevic T; Ugrin M; Virijevic M; Vidovic A; Tomin D; Suvajdzic Vukovic N; Pavlovic S; Tosic N Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):312-319. PubMed ID: 28163010 [TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR. Handschuh L; Kaźmierczak M; Milewski MC; Góralski M; Łuczak M; Wojtaszewska M; Uszczyńska-Ratajczak B; Lewandowski K; Komarnicki M; Figlerowicz M Int J Oncol; 2018 Mar; 52(3):656-678. PubMed ID: 29286103 [TBL] [Abstract][Full Text] [Related]
10. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia. Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900 [TBL] [Abstract][Full Text] [Related]
11. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia. Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998 [TBL] [Abstract][Full Text] [Related]
12. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission. Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332 [TBL] [Abstract][Full Text] [Related]
19. The Wilms Tumor-1 (WT1) rs2234593 variant is a prognostic factor in normal karyotype acute myeloid leukemia. Niavarani A; Horswell S; Sadri R; Bonnet D Ann Hematol; 2016 Jan; 95(2):179-90. PubMed ID: 26499507 [TBL] [Abstract][Full Text] [Related]
20. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis]. Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]